Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues
Molecular Pharmacology2002Vol. 61(5), pp. 1033–1040
Citations Over Time
Heather A. Dunkerley, Douglas G. Tilley, Daniel Palmer, Hanguan Liu, Sandra L. Jimmo, Donald H. Maurice
Related Papers
- → Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium(2005)113 cited
- → Dual Expression and Differential Regulation of Phosphodiesterase 3A and Phosphodiesterase 3B in Human Vascular Smooth Muscle: Implications for Phosphodiesterase 3 Inhibition in Human Cardiovascular Tissues(2000)63 cited
- → Regulation of murine cardiac function by phosphodiesterases type 3 and 4(2011)19 cited
- → Expression and activity of cGMP-dependent phosphodiesterases is up-regulated by lipopolysaccharide (LPS) in rat peritoneal macrophages(2006)22 cited
- → Cross-regulation of cAMP and cGMP levels by cAMP-specific phosphodiesterase-3 (PDE3) and cGMP-specific PDE5(2001)2 cited